Kornimate/medical-research-clean huggingface dataset:
examining validity and reliability of the shared decision making process survey in adults with depression

Conditions: Depression

Summary: the purpose of this study is to test two differently worded versions of the shared decision making process scale in a sample of adults who have recently made a decision about treatment of depression. the main goals are to gather evidence of reliability, to test whether the generic version has similar psychometric performance to the original, and to extend generalizability of the findings to younger adults.

the purpose of this study is to test two differently worded versions of the shared decision making process scale in a sample of adults who have recently made a decision about treatment of depression. the main goals are to gather evidence of psychometric performance of the scale, compare performance of different wording for items, and to extend generalizability of the findings to younger adults. subjects are randomly assigned to one of the two versions of the shared decision making process scale and complete a set of measures regarding their experiences with decision making for depression, demographics, and health status. a subset of respondents will complete the shared decision making process scale and selected other items again 1 week later to examine short term test-retest reliability. staff will work with a national sampling firm to recruit subjects and obtain 500 responses to the baseline survey (n=250 for each version) and a subset will complete a retest survey (n=200; 50 from each age and survey type group). eligible subjects are adults aged 18-75 who talked with a health care provider about treatment for depression in the preceding 12 months. the sample is not a national probability sample; however, the recruitment efforts will ensure about 50% of respondents aged 18-39 and 50% aged 40-75, and to ensure at least 25% of the sample is racial/ethnic minorities (black or african american, asian, hispanic or latino). the investigators will examine validity and reliability of the different versions. the sample size was determined to ensure sufficient power to detect differences in key subgroups, including age (younger adults vs. older adults) and version (a vs. b). to detect a difference of about 0.33 standard deviations at 0.05 significance with 80% power would require 125 per group.

Eligibility criteria:
inclusion criteria: * must have spoken to a healthcare provider about treatment for depression in the past 12 months * must have started or stopped medication for depression between january 2018 and their surveyed date. exclusion criteria: * none

Keywords: shared decision making
expanded access of sotorasib

Conditions: Non Small-cell Lung Cancer; Locally Advanced Unresectable NSCLC; Locally Advanced Metastatic NSCLC

Summary: the primary objective of this study is to provide expanded access to and characterize the safety profile of sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (nsclc) with kras p.g12c mutation in a real-world setting.


Eligibility criteria:
inclusion criteria * age ≥ 18 years * ineligibility for participation in any amgen-sponsored ongoing clinical study of the investigational product * pathologically documented, locally-advanced and unresectable or metastatic non small-cell lung cancer (nsclc) with kras p.g12c mutation confirmed through molecular testing * exhausted other standard of care options for locally advanced and unresectable or metastatic nsclc disease including platinum-based combination chemotherapy and programmed cell death protein 1/programmed death-ligand 1 (pd 1/pd-l1) immunotherapy (unless medically contraindicated) * eastern cooperative oncology group (ecog) performance status ≤ 2 exclusion criteria * mixed small-cell lung cancer or mixed nsclc histology * active brain metastases * active hepatitis b or hepatitis c virus * current active malignancy other than nsclc * currently or previously enrolled in a prior sotorasib study unless radiographic disease progression confirmed, able to remain on long term follow up of their original protocol and receives medical monitor approval * female participants planning to become pregnant while on study through 7 days after the last dose of sotorasib

Keywords: nsclc kras p.g12c mutation
iop changes with different anesthetic agents during laparoscopic colorectal surgery

Conditions: Intraocular Pressure

Summary: this study is aimed to evaluate how intraocular pressure (iop) is changed depending on surgical position (trendelenburg versus reverse trendelenburg) in the same patient and to compare the effects of different anesthetics on iop (desflurane versus propofol) in patients undergoing laparoscopic colorectal surgery. the study design is a double-blind randomized controlled trial. the patients were randomly assigned to desflurane or propofol administrated groups and all patient are administered intravenous remifentanil continuously as adjuvant analgesics during anesthesia. for this study 50 to 80-year-old patients undergoing laparoscopic colorectal surgery without eye disease were enrolled. mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and iop (using a tono-pen® avia tonometer) on both eyes were measured at defined intervals during the procedure.

perioperative visual loss is a rare but devastating complication associated with certain type of operative procedures. laparoscopic or robotic surgeries for colorectal cancer, prostate cancer and diseases of the female genital organs in the pelvic cavity are performed in a steep trendelenburg position and pneumoperitoneum, which increases the intraocular pressure (iop) by 13-26 mmhg compared with the preoperative iop value. high intraocular pressure is believed to correlate with decreased perfusion to the optic nerve, and thus could lead to ischemic optic neuropathy. the objective of the study is to test which anesthetic agent (desflurane or propofol) can attenuate the changes in iop during laparoscopic colorectal surgery and identify correlated parameters. fifty patients (30-80 years; american society of anesthesiologists' physical status 1-2) scheduled for laparoscopic colorectal surgery will be enrolled and allocated randomly into two groups (group d and group p). after measurement of initial iop with topical opthalmic anesthetics, general anesthesia will be induced with pentothal sodium 5-6mg/kg (group d) or propofol (group p) 2-2.5mg/kg. after administration of muscle relaxant and intubation, intraocular pressure will be measured and anesthesia will be maintained with desflurane (group d) or propofol (group p) and all patients will be administered intravenous remifentanil concurrently during anesthesia. during anesthesia, iop will be measured at different patient positions. at the time of each iop measurements, the following data set will be collected: mean arterial pressure (map), end tidal carbon dioxide (etco2), peak inspiratory pressure (pip).

Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopic colorectal surgery american society of anesthesiologist physical status class i or ii exclusion criteria: * opthalmic disease or previously undergone opthalmic surgery, uncontrolled hypertension, arrythmia, psychiatric disorder, uncontrolled obstructive lung disease

Keywords: intraocular pressure trendelenburg position pneumoperitoneum
real-time artificial intelligence system for detecting multiple ocular fundus lesions by ultra-widefield fundus imaging

Conditions: Artificial Intelligence; Diagnostic Imaging; Abnormality of the Fundus; Diagnostic Screening Programs

Summary: this prospective multicenter study will evaluate the efficacy of a real-time artificial intelligence system for detecting multiple ocular fundus lesions by ultra-widefield fundus imaging in real-world settings.

the ocular fundus can show signs of both ocular diseases (e.g., lattice degeneration, retinal detachment and glaucoma) and systemic diseases (e.g., hypertension, diabetes and leukemia). the routine fundus examination is conducive for early detection of these diseases. however, manual conducting fundus examination needs an experienced retina ophthalmologist, and is time-consuming and labor-intensive, which is difficult for its routine implementation on large scale. this study will develop an artificial intelligence system integrating with ultra-widefield fundus imaging to automatically screen for multiple ocular fundus lesions in real time and evaluate its performance in different real-world settings. the efficacy of the system will compare to the final diagnoses of each participant made by experienced ophthalmologists.

Eligibility criteria:
inclusion criteria: all the participants who agree to take ultra-widefield fundus images. exclusion criteria: 1. patients who cannot cooperate with a photographer such as some paralytics, the patients with dementia and severe psychopaths. 2. patients who do not agree to sign informed consent.

Keywords: artificial intelligence deep learning ultra-widefield fundus imaging ocular fundus lesions diagnostic screening programs
blood samples from patients with non-small cell lung cancer and from healthy volunteers

Conditions: Lung Cancer

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at blood samples from patients with non-small cell lung cancer and from healthy volunteers.

objectives: * measure plasma cathepsin d levels in patients with non-small cell lung cancer and in healthy volunteers using mass spectometry. * measure fatty acid synthase levels in these patients and healthy volunteers using mass spectometry. outline: blood samples are collected from patients and healthy volunteers to measure the levels of cathepsin d and fatty acid synthase by proteomic profiling and mass spectrometry.

Eligibility criteria:
inclusion criteria: non-small cell lung cancer patients * documented diagnosis of non-small cell lung cancer, any stage and any time point in the course of treatment (i.e., at diagnosis, during any treatment, and during post treatment surveillance) * measurable disease by ct scan within the past 4 weeks healthy volunteer * non-smoking, defined as \< 5 packs/year history of smoking and cessation of smoking ≥ 6 months ago or a never smoker * not regularly exposed (i.e., daily) to second-hand smoke exclusion criteria: * severe underlying lung disease (i.e., chronic obstructive pulmonary disease with fev_1 \< 1.0 l, pulmonary fibrosis, bronchiectasis, cystic fibrosis, etc.) as determined by enrolling researcher. written consent must be given for both subjects and controls.

Keywords: recurrent non-small cell lung cancer stage i non-small cell lung cancer stage ii non-small cell lung cancer stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
the effect of histopathologic analysis and tissue cultures on inpatient management of cellulitis and pseudocellulitis

Conditions: Cellulitis; Pseudocellulitis

Summary: the investigators wish to study the value of dermatologic testing assessments in differentiating between cellulitis and pseudocellulitis in the inpatient setting. the investigators propose that by utilizing cutaneous biopsies and tissue cultures in patients that have been admitted to inpatient internal medicine teams, the investigators may be able to improve multiple measures of hospital efficiency in patients presenting with cellulitis-like symptoms, by more accurately recognizing cellulitis from pseudocellulitis. the patient will undergo encrypted digital imaging for his or her condition. this image will then be sent to the study investigators, along with basic clinical information on the skin evaluation form. the study investigators will develop a differential diagnosis and then the patient will undergo a skin biopsy. the patient will then be randomized to one of two arms using a random number generator: a) skin biopsies and tissue cultures recorded and published in patient's medical chart as they would be in a standard of care procedure b) skin biopsies and tissue cultures consultation performed but not published in the patient's medical chart unless medically necessary. information will be collected from medical records in ihis. patients will be contacted by phone 30 days after discharge.


Eligibility criteria:
inclusion criteria: * admitted inpatient to the ohio state university wexner medical center internal medicine ward with cellulitis-like symptoms, including but not limited to the following: tenderness, redness, swelling, expansive lesion. * affecting one or more extremities * are at least 90 days post any associated operation of the extremity * are above the age of 18 * participants will be patients with cellulitis or pseudocellulitis. * patients who have recurrent cellulitis will be eligible for enrollment into the study, but only once. exclusion criteria: * patients who are pregnant * prisoners * patients may not have trauma, ulcer, or puncture wound to the area * may not be transferred from another hospital * may not be admitted to the cancer hospital or with a known active solid organ or hematologic cancer other than nonmelanoma skin cancer
long-term cognitive and functional status after covid-19 treatment at danish icus

Conditions: Covid19

Summary: this study is a prospective observational cohort study of 6 and 12 months long-term outcome of danish speaking patients with covid-19.

to describe frailty, cognitive function, functional status, fatigue, mortality and the quality of life 6 and 12 months after icu admission of the covid-19 patients enrolled in the danish icu covid-19 database. furthermore to investigate the association between ventilator days and clinical frailty score (cfs) and the minimoca, respectively at 6 and 12 months after icu admission

Eligibility criteria:
inclusion criteria: * \> 18 years * enrolled in the 'danish icu covid-19 database' exclusion criteria: * non danish speaking patients

Keywords: covid-19 danish icu long-term follow-up
study of the pharmacokinetics and safety of voriconazole in children 2 to 11 years old who are at high risk for systemic fungal infection

Conditions: Candidiasis; Candidemia

Summary: in this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down. since we know the dose in adults, and we think we know the matching doses in the young patients ages 2 to 12 years old, we will compare the amount of drug that goes into the system with what we know works in adults. we give the drug by a needle directly into the blood, then few days later we stop that and give the drug by mouth. meanwhile, we draw a little bit of blood at certain times to measure the drug in it.


Eligibility criteria:
inclusion criteria: * male or female from 2 to \<12 years of age. * require treatment for the prevention of systemic fungal infection. * expected to develop neutropenia (anc \<500 cells/μl) lasting more than 10 days following chemotherapy. * anticipated to live for more than 3 months. exclusion criteria: * evidence of any clinically significant liver or renal function or other abnormalities such as cardiac arrhythmia, hypokalemia, hypomagnesemia or hypocalcemia. * documented bacterial or viral infection not responding to appropriate treatment. * hypersensitivity to or severe intolerance of azole antifungal agents. * receiving other azoles or drugs that is are prohibited in the voriconazole label or associated.

Keywords: open-label pharmacokinetics intravenous to oral switch safety voriconazole immunocompromise children high risk for systemic fungal infection.
a study to test the effectiveness and safety of a new medication in the treatment of schizophrenia

Conditions: Schizophrenia

Summary: a 6-week in-patient and out-patient study to test the effectiveness and safety of a new medication in the treatment of schizophrenia

study will evaluate the efficacy of a new compound versus placebo in the treatment of patients with schizophrenia (diagnosed by dsm-iv criteria) as measured by reductions from baseline on the total score of the brief psychiatric rating scale (bprs) as extracted from the positive and negative syndrome scale (panss).

Eligibility criteria:
inclusion criteria: * satisfy dsm-iv criteria for schizophrenia as established by scid-cv * the patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment * if female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception exclusion criteria: * the patient has used an investigational drug within the past 30 days * the patient has participated in a previous study of this compound

Keywords: schizophrenia latuda lurasidone
guelph family health study: pilot study

Conditions: Obesity

Summary: the overall objective of the proposed study is to test, among canadian families, the comparative effectiveness of 2 different versions (doses) of a family-based obesity prevention intervention that is tailored to families' behavioural risk profile. to achieve this objective, we will conduct a randomized controlled trial of families with children aged 18 months- 5 years. families will be randomized to 1 of 3 conditions: 1) monthly emails with general health information (attention control), 2) tailored weekly emails and 2 home visits with a health educator (email +2), 3) tailored weekly emails and 4 home visits (email +4). the intervention will last 6 months, with follow-up at 12-months post-intervention (18 months from baseline). we will examine the impact of the intervention on the children's body composition, weight-related behaviours, and biomarkers of diabetes and cardiovascular disease risk. we hypothesize that, compared to children in the attention control, children in the email +2 and email +4 conditions will achieve: 1. a smaller increase in adiposity (primary outcome), age- and gender-specific body mass index (bmi),over a 6-month intervention period. 2. higher frequency of family meals, child's sleep duration, physical activity, and fruit and vegetable intake and lower child's sugar-sweetened beverage intake, and sedentary behaviour over a 6-month intervention period. (secondary outcomes) 3. lower diastolic blood pressure, glycosylated hemoglobin, fasting glucose, fasting insulin, low density lipoprotein (ldl) cholesterol, triglycerides, c-reactive protein, trans and saturated fats, and higher high density lipoprotein (hdl) cholesterol over a 6-month intervention period. we further hypothesize that there will be no significant difference in these outcomes between children in the conditions with 2 (email +2) or 4 (email +4) home visits.


Eligibility criteria:
inclusion criteria: * families who have a child aged 18 months through 5 years * live the guelph area * have a parent who can respond to questionnaires in english exclusion criteria: * families who plan to move during the study period * children with severe health conditions (such as severe cerebral palsy) that would prohibit them from participating in study activities
oxidized cellulose hemostatic agent in thyroid surgery: a prospective randomized controlled study

Conditions: Thyroid Nodule; Thyroid Diseases; Goiter

Summary: this single-blind prospective randomized study was designed to assess the efficacy and safety of the use of surgicel® compared to the use of conventional surgical procedures (ligatures and bipolar electrocautery alone) to achieve hemostasis in thyroid surgery

patients who require a thyroidectomy will be enrolled after informed consent will begiven. prior to thyroidectomy, patients will be randomized to two groups: 1) use of conventional surgical procedures to achieve hemostasis,i.e., ligatures and bipolar electrocauterization alone, and 2) use of oxidized cellulose patch (surgicel©) in addition to classical methods (ligature; bipolar electrocautery). all anticoagulants will be discontinued 10 days prior to the operation, if this will not be possible the patient will be excluded. the investigators will perform the specified procedure in accordance with accepted clinical practice standards. at the end of the thyroidectomy, a meticulous hemostasis will be achieved. before wound closure, the sealed affiliation envelopes will be opened and 1-2×2 cm oxidized cellulose patch will be placed over the thyroid bed depending on patient randomization. next, a suction drain will be placed. the drains will be removed when the secretion volume/day will be less than 20 cc. all operations will be performed under general anesthesia by three head and neck surgeons who had experience in thyroid surgery. outcome measures will include duration of operation, hemodynamic variables on emergence (blood pressure and heart rate), volume of secretion in the drain, time to removal of wound drain, length of postoperative hospital stay, and incidence of postoperative complications, i.e. hemorrhage, transient hypoparathyroidism, wound infection, seroma, and recurrent laryngeal nerve palsy. evaluation of the postoperative course and recording of data will be done by one surgeons blinded to the intervention (ma). follow-up for this study will be ended one month after the surgery.

Eligibility criteria:
inclusion criteria: * all patients who required a thyroidectomy exclusion criteria: * unwilling or unable to consent * age \< 18 years * known allergy to oxidized cellulose * inability to discontinue use of anticoagulants 10 days before surgery * coagulopathy that could not be corrected
immunohistochemical expression of cxcl5 as a valuable prognostic marker in urinary bladder urothelial carcinoma

Conditions: Urinary Bladder Urothelial Carcinoma

Summary: urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis. cxcl5 have been implicated in progression of many cancers, but their significance in urinary bladder uc remains unclear.

bladder carcinoma has become a common cancer globally, incidence rates are highest in europe, the united states and egypt. in egypt, bladder carcinoma was considered the third most common tumor; egyptian males have the highest mortality rates. uc of the urinary bladder represents about 90% of all bladder cancers. cxcl5 is a chemokine, belonging to ‗elr+' subgroup. it plays an important role in angiogenesis and tumor migration. numerous reports have indicated that cxcl5 plays important roles in cancer progression, including cholangiocarcinoma, prostate cancer, and gastric cancer. studying the ihc expression of cxcl5 in uc to assess its role in tumor cell proliferation, migration and spread is needed.

Eligibility criteria:
inclusion criteria:patients with primary invasive and non-invasive urinary bladder urothelial carcinomas. - exclusion criteria: * - patients received pre-operative chemotherapy or radiotherapy. * patients with insufficient clinical data. * specimens with extensive necrosis * tiny specimens which are insufficient for accurate diagnosis.

Keywords: cxcl5 urothelial carcinoma